|
Name |
Norbornyl acetate
|
Molecular Formula | C9H14O2 | |
IUPAC Name* |
2-bicyclo[2.2.1]heptanyl acetate
|
|
SMILES |
CC(=O)OC1CC2CCC1C2
|
|
InChI |
InChI=1S/C9H14O2/c1-6(10)11-9-5-7-2-3-8(9)4-7/h7-9H,2-5H2,1H3
|
|
InChIKey |
YXNICIBZSREEPY-UHFFFAOYSA-N
|
|
Synonyms |
Norbornyl acetate; 2-Norbornyl acetate; 34640-76-1; Bicyclo[2.2.1]hept-2-yl acetate; Bicyclo[2.2.1]heptan-2-ol, acetate; Norborneol acetate; Bicyclo(2.2.1)heptan-2-ol, acetate; Bicyclo(2.2.1)heptan-2-ol, 2-acetate; Bicyclo(2.2.1)hept-2-yl acetate; Bicyclo[2.2.1]heptan-2-ol, 2-acetate; EINECS 252-123-6; NSC 529406; BICYCLO[2.2.1]HEPTAN-2-YL ACETATE; SCHEMBL2623615; DTXSID60885592; NSC529406; AKOS024341080; NSC-529406; Acetic acid, bicyclo[2.2.1]hept-2-yl ester
|
|
CAS | 34640-76-1 | |
PubChem CID | 101199 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 154.21 | ALogp: | 1.9 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 2 |
Heavy Atoms: | 11 | QED Weighted: | 0.542 |
Caco-2 Permeability: | -4.516 | MDCK Permeability: | 0.00005310 |
Pgp-inhibitor: | 0.009 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.04 |
Blood-Brain-Barrier Penetration (BBB): | 0.994 | Plasma Protein Binding (PPB): | 38.76% |
Volume Distribution (VD): | 0.955 | Fu: | 57.92% |
CYP1A2-inhibitor: | 0.084 | CYP1A2-substrate: | 0.144 |
CYP2C19-inhibitor: | 0.033 | CYP2C19-substrate: | 0.737 |
CYP2C9-inhibitor: | 0.018 | CYP2C9-substrate: | 0.806 |
CYP2D6-inhibitor: | 0.011 | CYP2D6-substrate: | 0.572 |
CYP3A4-inhibitor: | 0.113 | CYP3A4-substrate: | 0.295 |
Clearance (CL): | 6.19 | Half-life (T1/2): | 0.609 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.429 |
Drug-inuced Liver Injury (DILI): | 0.591 | AMES Toxicity: | 0.042 |
Rat Oral Acute Toxicity: | 0.01 | Maximum Recommended Daily Dose: | 0.387 |
Skin Sensitization: | 0.944 | Carcinogencity: | 0.394 |
Eye Corrosion: | 0.881 | Eye Irritation: | 0.974 |
Respiratory Toxicity: | 0.304 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000578 | 0.417 | D0R7WU | 0.444 | ||||
ENC001166 | 0.360 | D04URO | 0.246 | ||||
ENC002662 | 0.308 | D07CNL | 0.243 | ||||
ENC003152 | 0.302 | D0O5SZ | 0.230 | ||||
ENC005378 | 0.281 | D0RD5W | 0.230 | ||||
ENC001908 | 0.281 | D0K0KH | 0.227 | ||||
ENC000644 | 0.265 | D05HXX | 0.220 | ||||
ENC004001 | 0.264 | D06PTA | 0.210 | ||||
ENC004129 | 0.259 | D0S0AS | 0.210 | ||||
ENC003367 | 0.254 | D04XPW | 0.208 |